Adaptive Biotechnologies Corporation
25.51USD
+1.1000 (+4.51%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ADPT.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 72 | 71 | 72 | 94 | 59 | 52 | 47 | 46 |
| Cost of Revenue | 20 | 19 | 18 | 18 | 18 | 17 | 18 | 17 |
| Gross Profit | 51 | 52 | 53 | 76 | 41 | 35 | 29 | 30 |
| Operating Income | -16 | -19 | -13 | 10 | -25 | -30 | -34 | -33 |
| Net Income | -40 | -20 | -14 | 10 | -26 | -30 | -34 | -32 |
| EPS (Diluted) | -$0.25 | -$0.13 | -$0.09 | $0.06 | -$0.17 | -$0.20 | -$0.22 | -$0.22 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)